





# MIDAS

Mammography based  
Image Diagnosis & Analysis System  
for  
Breast Cancer



# Introduction




*Breast cancer* is the most commonly diagnosed cancer among women; it can have long-term implications while being *fatal*.

However, *early detection*, achieved through recent advancements in technology, can help *reduce mortality*.

*Mammography* is still the most widely used modality for cancer screening.




# Problem *vs.* solution






# Problem




- Burden and costs in the routine of "*blinded double reading*"
- High miss rate for "*microcalcifications*"
- Variations in "*breast tissue density*"



# Solution




xAI



MIDAS MVP includes the following:

- ✓ An *eXplainable* decision support model trained on screening mammographies.
- ✓ Web-based platform with a *VIEWER* and an oncology workflow
- ✓ Digital enhancement functionality via the viewer
- ✓ Ease of integrability via service end-points and direct PACS connectivity
- ✓ Polygon-based ROI *annotation* tool



Product

# Product overview



## Fundamentals



- ✓ State-of-the-art AI model trained with an **ensemble** of **deep learning backbones**
- ✓ "**eXplainable**" decision model emphasizing **salient regions** on mammograms
- ✓ Digital **enhancement** techniques to **eliminate** OR **emphasize** morphologies for radiological interpretation (dense/dense heterogeneity, microcalcifications, artifacts & background)
- ✓ Ease of integrability via service end-points and direct **PACS connectivity**



## Highlights

- ✓ Decision model trained on a **huge volume** of labelled mammography data ( **>200K** instances )  
- *curated in collaboration with **Hacettepe University** Faculty of Medicine **Dept. of Radiology***
- ✓ Diversified in terms of malignancy subtypes
- ✓ Final model with **high AUC** and **PR-AUC** validated on publicly available datasets
- ✓ **Rapid inference** time







- Original Mask
- Other Masks
- Benign Saliency Map
- Malign Saliency Map

BreastID: 10117998\_20160902\_R  
Definitions: Sınırları Belirsiz

CC BIRADS: 4  
MLO BIRADS: 5

Actual BI-RADS: Malign  
Benign: No  
Malign: Yes





- Original Mask
- Other Masks
- Benign Saliency Map
- Malign Saliency Map

BreastID: 10128039\_20181009\_L  
Definitions: makrokalsifikasyon  
mikrokalsifikasyon

CC BIRADS: 2  
MLO BIRADS: 2

Actual BI-RADS: Benign  
Benign: Yes  
Malign: No







- Original Mask
- Other Masks
- Benign Saliency Map
- Malign Saliency Map

BreastID: 10226827\_20171222\_L  
Definitions: Keskin Simirli

CC BIRADS: 4  
MLO BIRADS: 4

Actual BI-RADS: Malign  
Benign: No  
Malign: Yes





- Original Mask
- Other Masks
- Benign Saliency Map
- Malign Saliency Map

BreastID: 10233113\_20171222\_R  
Definitions: lobüle kitle

CC BIRADS: 4  
MLO BIRADS: 4

Actual BI-RADS: Malign  
Benign: No  
Malign: Yes

# Success metrics



**ROC AUC\*** value is **0.85** and the **PR AUC\*\*** value is **0.89** (CI: 95%) in the final MIDAS model.

The precision exceeds radiologists' performance & shows an **upward trend** with novel trainings

[\*\*] PR AUC is commonly used for heavily imbalanced datasets for optimizing the **positive** class.

[\*] The average ROC AUC value for radiologist reading is found to be **0.63** (CI: 95%) according to "McKinney, S.M., Sieniek, M., Godbole, V. et al. International evaluation of an AI system for breast cancer screening. *Nature* 577, 89–94 (2020)"



# Investments so far



## National Grants

- ✓ TUBITAK 1501 Industrial R&D Projects Grant Programme
- ✓ Health Institutes of TR (Republic of Turkey Ministry of Health) prioritized R&D Call for **Medical AI**
- ✓ TUBITAK 1515 - Frontier R&D Laboratory Support Programme
  - *fund application is under evaluation*

## Equity Capital



- ✓ ICterra A.Ş.
- *H. Vedat USLU (CEO)*



# Contact us

